Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.
// request.cf · coarse context
A page that knows where it met you.
Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.
UCD0068 shows weak affinity for the serotonin5-HT2A receptor (Ki = 890nM).[1] The drug's affinity for this receptor was 166-fold lower than that of LSD.[1] UCD0068 acts as a moderate-to-high efficacypartial agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.[1] Its EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy values at these receptors were found to be 104nM (60%) at the serotonin 5-HT2A receptor, 9.24nM (61%) at the serotonin 5-HT2B receptor, and 176nM (89%) at the serotonin 5-HT2C receptor.[1] The drug was 188-fold, 17-fold, and 283-fold less potent as an agonist of these receptors than LSD, respectively.[1] Hence, it is a relatively selective serotonin 5-HT2B receptor agonist.[1]
In contrast to LSD and another partial lysergamide known as UCD0120 (dides-B,C-LSD), UCD0068 failed to induce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[1] As such, UCD0068 would be expected to be non-hallucinogenic in humans.[1]
The chemical synthesis of UCD0068 has been described.[1][4] A variety of other deconstructed analogues of LSD along with UCD0068 have also been described.[1]
1234567891011121314Basargin AG, Domokosa A, Hennessey JJ, Aarrestad IK, Sambyal R, Khatib YA, etal. (September 2026). "Deconstruction of lysergic acid diethylamide". Proceedings of the National Academy of Sciences of the United States of America. 123 (38) e2603412123. doi:10.1073/pnas.2603412123. PMID42709856.
12Nichols DE (May 1973). Potential Psychotomimetics: Bromomethoxyamphetamines and Structural Congeners of Lysergic Acid (Ph.D. thesis). University of Iowa. p.23. OCLC1194694085. Horii, et al, (90) have synthesized 2-carboxy-4-methyl-2,3,4,4,5,6-hexahydrobenzo[f] quinoline 30a lacking only the indole nucleus. These workers claimed patents on derivatives of this compound as uterine contracting agents whose potency was on the order of 1/15–1/16 that of ergonovine. Although no gross behavioral effects have been reported for several of these compounds it should be noted that none contain an indole nucleus, yet many are reported to retain a high degree of pharmacological activity. It would thus appear that the significance of the indole moiety is questionable. This [...] compares favorably with other oxytocic analogs of lysergic acid, such as the tricyclic systems prepared by Horii, et al, (90) mentioned earlier. The diethylamide 30b, certainly resembles the structure of ergonovine to a greater extent than do 33 or 34, yet it is less active.
123Horii Z, Kurihara T, Yamamoto S, Ninomiya I (November 1967). "Studies on ergot alkaloids and related compounds. XIV. Synthesis of N-alkyl-4-methyl-2,3,4,4a,5,6-hexahydrobenzo[f]quinoline-2-carboxamides and stereochemistry of diethyl 4-methyl-1-oxo-1,2,3,4,4a,5,6,10b-octahydro-benzo[f]quinoline-2,2-dicarboxylate". Chemical & Pharmaceutical Bulletin. 15 (11). Tokyo: 1641–1650. doi:10.1248/cpb.15.1641. PMID5583819. [...] Of these amide derivatives, the diethylamide (VIII) was also prepared by an alternative route as follows. [...] Experimental. [...] N,N-Diethyl-4-methyl-2,3,4,4a,5,6-hexahydrobenzo(f)quinoline-2-carboxamide (VIII)—[...]
